Bladder preservation in muscle invasive bladder cancer

Sung J. Hong, Byungha Chung, Dong Hyeon Lee

Research output: Contribution to journalArticle

Abstract

Twenty eight patients with muscle invasive transitional cell carcinoma of the bladder (stage T2-T4NOMO) were treated with bladder sparing protocols after initial transurethral resection (TUR) of bladder tumor. The trial consisted of initial radiotherapy (6480cGy) with 2 courses of cisplatin plus additional 2 courses of MCV chemotherapy. The distribution of patients were cT2 in 10, cT3 in 15, and cT4 in 3 patients. All patients were pathologically proven as having muscle invasive bladder cancer. If there was no visible protruding mass in the bladder after TUR, it was regarded as a complete resection state. Repeat TUR or deep biopsy was conducted on the basis of cystoscopic findings with an interval of 3 months after initiation of therapy. We recommended radical cystectomy in patients with persistent or newly developed tumor. With a mean follow up of 44.1 months (10 to 64 months), the disease free survival rate was 60.7% (17/28) including four cystectomy cases - 90% (9/10) in cT2, 53.3% (8/15) in cT3 and none in cT4. Two year survival rate was 90.9% (20/22) and three year 59.3% (11/17). Local tumor recurrence or distatnt metastasis was observed in 11 patients. Side reactions such as neutropenia was observed in 10 (35.7%) patients, radiation cystitis orproctitis in 4 (14.2%). The response was closely related with the initial stage at presentation and tumor grade. Extensive TUR is strongly recommended to achieve the maximal therapeutic effect. Our data demonstrates that bladder preservation trial in locally advanced bladder cancer has relatively satisfactory results although longer follow up is required to determine the efficacy of current protocol in long term survival and quality of life.

Original languageEnglish
Number of pages1
JournalBritish Journal of Urology
Volume80
Issue numberSUPPL. 2
Publication statusPublished - 1997 Dec 1

Fingerprint

Urinary Bladder Neoplasms
Urinary Bladder
Muscles
Cystectomy
Survival Rate
Neoplasms
Cystitis
Transitional Cell Carcinoma
Therapeutic Uses
Neutropenia
Cisplatin
Disease-Free Survival
Radiotherapy
Quality of Life
Radiation
Neoplasm Metastasis
Biopsy
Recurrence
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Hong, Sung J. ; Chung, Byungha ; Lee, Dong Hyeon. / Bladder preservation in muscle invasive bladder cancer. In: British Journal of Urology. 1997 ; Vol. 80, No. SUPPL. 2.
@article{52d62bef707f4e38bae9bed9a1d44ef5,
title = "Bladder preservation in muscle invasive bladder cancer",
abstract = "Twenty eight patients with muscle invasive transitional cell carcinoma of the bladder (stage T2-T4NOMO) were treated with bladder sparing protocols after initial transurethral resection (TUR) of bladder tumor. The trial consisted of initial radiotherapy (6480cGy) with 2 courses of cisplatin plus additional 2 courses of MCV chemotherapy. The distribution of patients were cT2 in 10, cT3 in 15, and cT4 in 3 patients. All patients were pathologically proven as having muscle invasive bladder cancer. If there was no visible protruding mass in the bladder after TUR, it was regarded as a complete resection state. Repeat TUR or deep biopsy was conducted on the basis of cystoscopic findings with an interval of 3 months after initiation of therapy. We recommended radical cystectomy in patients with persistent or newly developed tumor. With a mean follow up of 44.1 months (10 to 64 months), the disease free survival rate was 60.7{\%} (17/28) including four cystectomy cases - 90{\%} (9/10) in cT2, 53.3{\%} (8/15) in cT3 and none in cT4. Two year survival rate was 90.9{\%} (20/22) and three year 59.3{\%} (11/17). Local tumor recurrence or distatnt metastasis was observed in 11 patients. Side reactions such as neutropenia was observed in 10 (35.7{\%}) patients, radiation cystitis orproctitis in 4 (14.2{\%}). The response was closely related with the initial stage at presentation and tumor grade. Extensive TUR is strongly recommended to achieve the maximal therapeutic effect. Our data demonstrates that bladder preservation trial in locally advanced bladder cancer has relatively satisfactory results although longer follow up is required to determine the efficacy of current protocol in long term survival and quality of life.",
author = "Hong, {Sung J.} and Byungha Chung and Lee, {Dong Hyeon}",
year = "1997",
month = "12",
day = "1",
language = "English",
volume = "80",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "SUPPL. 2",

}

Bladder preservation in muscle invasive bladder cancer. / Hong, Sung J.; Chung, Byungha; Lee, Dong Hyeon.

In: British Journal of Urology, Vol. 80, No. SUPPL. 2, 01.12.1997.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bladder preservation in muscle invasive bladder cancer

AU - Hong, Sung J.

AU - Chung, Byungha

AU - Lee, Dong Hyeon

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Twenty eight patients with muscle invasive transitional cell carcinoma of the bladder (stage T2-T4NOMO) were treated with bladder sparing protocols after initial transurethral resection (TUR) of bladder tumor. The trial consisted of initial radiotherapy (6480cGy) with 2 courses of cisplatin plus additional 2 courses of MCV chemotherapy. The distribution of patients were cT2 in 10, cT3 in 15, and cT4 in 3 patients. All patients were pathologically proven as having muscle invasive bladder cancer. If there was no visible protruding mass in the bladder after TUR, it was regarded as a complete resection state. Repeat TUR or deep biopsy was conducted on the basis of cystoscopic findings with an interval of 3 months after initiation of therapy. We recommended radical cystectomy in patients with persistent or newly developed tumor. With a mean follow up of 44.1 months (10 to 64 months), the disease free survival rate was 60.7% (17/28) including four cystectomy cases - 90% (9/10) in cT2, 53.3% (8/15) in cT3 and none in cT4. Two year survival rate was 90.9% (20/22) and three year 59.3% (11/17). Local tumor recurrence or distatnt metastasis was observed in 11 patients. Side reactions such as neutropenia was observed in 10 (35.7%) patients, radiation cystitis orproctitis in 4 (14.2%). The response was closely related with the initial stage at presentation and tumor grade. Extensive TUR is strongly recommended to achieve the maximal therapeutic effect. Our data demonstrates that bladder preservation trial in locally advanced bladder cancer has relatively satisfactory results although longer follow up is required to determine the efficacy of current protocol in long term survival and quality of life.

AB - Twenty eight patients with muscle invasive transitional cell carcinoma of the bladder (stage T2-T4NOMO) were treated with bladder sparing protocols after initial transurethral resection (TUR) of bladder tumor. The trial consisted of initial radiotherapy (6480cGy) with 2 courses of cisplatin plus additional 2 courses of MCV chemotherapy. The distribution of patients were cT2 in 10, cT3 in 15, and cT4 in 3 patients. All patients were pathologically proven as having muscle invasive bladder cancer. If there was no visible protruding mass in the bladder after TUR, it was regarded as a complete resection state. Repeat TUR or deep biopsy was conducted on the basis of cystoscopic findings with an interval of 3 months after initiation of therapy. We recommended radical cystectomy in patients with persistent or newly developed tumor. With a mean follow up of 44.1 months (10 to 64 months), the disease free survival rate was 60.7% (17/28) including four cystectomy cases - 90% (9/10) in cT2, 53.3% (8/15) in cT3 and none in cT4. Two year survival rate was 90.9% (20/22) and three year 59.3% (11/17). Local tumor recurrence or distatnt metastasis was observed in 11 patients. Side reactions such as neutropenia was observed in 10 (35.7%) patients, radiation cystitis orproctitis in 4 (14.2%). The response was closely related with the initial stage at presentation and tumor grade. Extensive TUR is strongly recommended to achieve the maximal therapeutic effect. Our data demonstrates that bladder preservation trial in locally advanced bladder cancer has relatively satisfactory results although longer follow up is required to determine the efficacy of current protocol in long term survival and quality of life.

UR - http://www.scopus.com/inward/record.url?scp=33749279679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749279679&partnerID=8YFLogxK

M3 - Article

VL - 80

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - SUPPL. 2

ER -